Psychiatry and Mental Health

Guest: Nancy Chiaravalloti, PhD

Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

Host: Ashley Baker, MSN, PMHNP
Guest: Morris Goldman, MD
Guest: Dara Sanandaji

A diagnosis of schizophrenia can be distressing, making clinical interventions crucial for both the patient and their family. With the assistance of an appropriate treatment plan and peer support, the patient can gain empowerment to take control of their life and pursue long-term goals. Joining Psychiatric Nurse Practitioner Ashley Baker to discuss next steps following a schizophrenia diagnosis is Dr. Morris Goldman, Associate Professor of Psychiatry at Northwestern Feinberg School of Medicine, and Dara Sanandaji, Peer Support Supervisor at the Recovery from Early Psychosis Program.

Host: Ashley Baker, MSN, PMHNP
Guest: Hannah Brown, MD

Unfortunately, when it comes to the diagnosis and treatment of schizophrenia, there is nothing to definitively give clinicians a diagnosis, so it’s important to have a clinical evaluation and rule out everything else. But once a first episode psychosis diagnosis has been made, what treatment options are available? Dive into this episode with Psychiatric Nurse Practitioner Ashley Baker who is joined by Dr. Hannah Brown, Director of the Wellness and Recovery After Psychosis Program at Boston Medical Center and Assistant Professor of Psychiatry at Boston University Chobanian and Avedisian School of Medicine.

Guest: Aderonke Pederson, MD

Major depressive disorder is a mental health condition that affects millions of Americans,¹ and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.^2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School.

References:

1. National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression
2. National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression
3. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. American Psychiatric Association Publishing. 2010. Accessed November 10, 2023. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf

January 2024 US.UNB.X.23.00150

Host: Annie Levesque, MD, MSc
Guest: Ethan A. Cowan, MD

Alcohol use disorder, or AUD, is a rising health crisis that often goes undiagnosed. And many patients that are diagnosed with AUD do not receive appropriate pharmacologic intervention or even a referral. Join Drs. Levesque and Cowan in this case-based educational program as they provide critical diagnostic and treatment strategies for use in the office/clinic setting and the Emergency Department.

Host: Bianca Weinstock-Guttman, MD

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Bianca Weinstock-Guttman, MD

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Bianca Weinstock-Guttman, MD

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

Host: Christoph U. Correll, MD

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

Host: Christoph U. Correll, MD

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

Host: Christoph U. Correll, MD
Host: Leslie Citrome, MD, MPH

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

Host: Christoph U. Correll, MD
Host: Leslie Citrome, MD, MPH

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

Host: Leslie Citrome, MD, MPH

This program will concentrate on practical clinical strategies aimed at utilizing long-acting injectable (LAI) antipsychotics at an earlier stage to improve outcomes for individuals with schizophrenia. These informative episodes will present optimal approaches for overcoming barriers to LAI utilization, identifying patients who would benefit from LAIs across the entire patient spectrum, employing assessment tools to measure patient improvement, and advocating for the early use of LAI antipsychotics as maintenance therapy in suboptimally treated or nonadherent schizophrenia patients.

Host: Andrew Wilner, MD, FACP, FAAN
Guest: Carri Polick, PhD, RN

Two recent studies linked childhood stress and stressors experienced across the lifespan to the severity of multiple sclerosis (MS) symptoms. In fact, both childhood and adult stressors were associated with MS disability and the so-called invisible symptoms of pain interference and psychiatric morbidity while only adult stressors were related to relapse burden. Joining Dr. Andrew Wilner to discuss these findings and how they may shift our approach to caring for patients with MS is Dr. Carri Polick, a postdoctoral fellow and VA scholar in the Duke National Clinician Scholars Program.

Guest: Christena Raines, NP

Perinatal mood disorders are among the most common complications during pregnancy and immediately following delivery. So front line providers need to be able to initiate treatment. Perinatal Psychiatric Nurse Practitioner and Adjunct Professor of Psychiatry at UNC Chapel Hill, Christena Raines, discusses her session at the 26^th Annual Nurse Practitioners in Women’s Healthcare Conference and the importance of recognizing and treating perinatal mood disorders in our female patients.